Literature DB >> 21853734

[Pancreatoduodenectomy--past, present and future].

I Popescu, T Dumitraşcu.   

Abstract

Pancreatico-duodenectomy represents one of the most important and complex surgical digestive procedure. Although rarely performed in the past, nowadays has become a routine surgery. Moreover, postoperative mortality significantly decreased (from over 30% to less than 5%), while the number of severe, life-threatening complications were reduced. This outcome was possible due to technical innovations acquired in time, and also due to a better per operative management of these patients, in tertiary surgical centers, with experienced operative teams. Some modifications of the standard procedure of resection, like posterior or artery first approach contributed to better results, facilitating en-block resection of the portal/ superior mesenteric vein, where needed. Moreover, posterior approach facilitates complete mesopancreas excision, involved in local recurrence after resection of pancreatic head adenocarcinoma. Regarding reconstruction after pancreaticoduodenectomy, there is no optimal type of anastomosis (pancreatico-gastrostomy vs pancreatico-jejunostomy), results being related mostly with the expertise of the operative team, as like the postoperative pancreatic fistula rate. Future studies are deemed to look on the real clinical impact of the total mesopancreas excision in achieving negative resection margins, decreasing local recurrence and increasing the long-term survival of patients resected for pancreatic head cancer.

Entities:  

Mesh:

Year:  2011        PMID: 21853734

Source DB:  PubMed          Journal:  Chirurgia (Bucur)        ISSN: 1221-9118


  3 in total

1.  Pseudoaneurysm of the splenic artery - an uncommon cause of delayed hemorrhage after pancreaticoduodenectomy.

Authors:  Radu Dumitru; Ana Carbunaru; Mugur Grasu; Mihai Toma; Mihnea Ionescu; Traian Dumitrascu
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2016-11-30

2.  Male gender and increased body mass index independently predicts clinically relevant morbidity after spleen-preserving distal pancreatectomy.

Authors:  Traian Dumitrascu; Mihai Eftimie; Andra Aiordachioae; Cezar Stroescu; Simona Dima; Mihnea Ionescu; Irinel Popescu
Journal:  World J Gastrointest Surg       Date:  2018-11-27

3.  Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment.

Authors:  Hung-Jun Lin; Tien-Li Liang; Yao-Yuan Chang; Der-Zen Liu; Jia-Yu Fan; Steve R Roffler; Shyr-Yi Lin
Journal:  Pharmaceutics       Date:  2022-06-05       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.